ETCTN A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance Adult CIRB - Early Phase Emphasis Administratively Completed Completed